These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 26547457)
1. Asymptomatic Atrial Fibrillation: The Case for Screening to Prevent Stroke. Ben Freedman S; Lowres N JAMA; 2015 Nov; 314(18):1911-2. PubMed ID: 26547457 [No Abstract] [Full Text] [Related]
3. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. Chevalier J; Delaitre O; Hammès F; de Pouvourville G Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113 [TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke. Levin LÅ; Husberg M; Sobocinski PD; Kull VF; Friberg L; Rosenqvist M; Davidson T Europace; 2015 Feb; 17(2):207-14. PubMed ID: 25349228 [TBL] [Abstract][Full Text] [Related]
5. Diving to the foot of an iceberg: the SEARCH for undiagnosed atrial fibrillation. Potpara TS; Lane DA Thromb Haemost; 2014 Jul; 112(1):1-3. PubMed ID: 24899512 [No Abstract] [Full Text] [Related]
6. Cost-effectiveness of ximelagatran for stroke prevention. Perret-Guillaume C; Wahl D JAMA; 2005 Jun; 293(23):2860-1; author reply 2861. PubMed ID: 15956626 [No Abstract] [Full Text] [Related]
7. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Shah SV; Gage BF Circulation; 2011 Jun; 123(22):2562-70. PubMed ID: 21606397 [TBL] [Abstract][Full Text] [Related]
9. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. O'Brien CL; Gage BF JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911 [TBL] [Abstract][Full Text] [Related]
11. Downsides of Detecting Atrial Fibrillation in Asymptomatic Patients. Mandrola J; Foy A Am Fam Physician; 2019 Mar; 99(6):354-355. PubMed ID: 30874403 [No Abstract] [Full Text] [Related]
12. Screening, optimization, support: a call for stroke prevention in atrial fibrillation. Induruwa I; Liu W; Khadjooi K Br J Hosp Med (Lond); 2018 Aug; 79(8):424-425. PubMed ID: 30070947 [No Abstract] [Full Text] [Related]
13. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012 [TBL] [Abstract][Full Text] [Related]
14. The economics of atrial fibrillation: a time for review and prioritization. Cadilhac DA Int J Stroke; 2012 Aug; 7(6):477-9. PubMed ID: 22805574 [TBL] [Abstract][Full Text] [Related]
15. People over 65 should be screened for atrial fibrillation, say stroke specialists. Christie B BMJ; 2012 Mar; 344():e1644. PubMed ID: 22391818 [No Abstract] [Full Text] [Related]
17. Anticoagulation for elderly patients with atrial fibrillation: not to be neglected. Taggar JS; Lip GY Europace; 2008 Jan; 10(1):1-2. PubMed ID: 17906285 [No Abstract] [Full Text] [Related]
18. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation. Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964 [TBL] [Abstract][Full Text] [Related]
19. International experts call for atrial fibrillation screening programme. Evans N Nurs Older People; 2017 May; 29(5):8-9. PubMed ID: 28560922 [TBL] [Abstract][Full Text] [Related]